Mostrar el registro sencillo del ítem
dc.contributor.author
Talevi, Alan
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.date.available
2023-02-17T13:09:27Z
dc.date.issued
2022-08
dc.identifier.citation
Talevi, Alan; Antiseizure medication discovery: Recent and future paradigm shifts; John Wiley & Sons; Epilepsia Open; 7; S1; 8-2022; S133-S141
dc.identifier.issn
2470-9239
dc.identifier.uri
http://hdl.handle.net/11336/188349
dc.description.abstract
Despite the ever-increasing number of available options for the treatment of epilepsies and the remarkable advances on the understanding of their pathophysiology, the proportion of refractory patients has remained approximately unmodified during the last 100 years. How efficient are we translating positive outcomes from basic research to clinical trials and/or the clinical scenario? It is possible that fresh thinking and exploration of new paradigms are required to arrive at truly novel therapeutic solutions, as seemingly proven by recently approved first-in-class antiseizure medications and drug candidates undergoing late clinical trials. Here, the author discusses some approximations in line with the network pharmacology philosophy, which may result in highly innovative (and, hopefully, safer and/or more efficacious) medications for the control of seizures, as embodied with some recent examples in the field, namely tailored multi-target agents and low-affinity ligands.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
John Wiley & Sons
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.subject
DISRUPTING INNOVATION
dc.subject
DRUG DISCOVERY
dc.subject
EPILEPSY
dc.subject
INNOVATION
dc.subject
LOW-AFFINITY LIGAND
dc.subject
MULTI-TARGET
dc.subject
MULTI-TARGET DRUGS
dc.subject
NETWORK PHARMACOLOGY
dc.subject
PARTIAL AGONIST
dc.subject
RADICAL INNOVATION
dc.subject
SYSTEMS PHARMACOLOGY
dc.subject.classification
Farmacología y Farmacia
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Básica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Antiseizure medication discovery: Recent and future paradigm shifts
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2023-02-09T15:47:24Z
dc.identifier.eissn
2470-9239
dc.journal.volume
7
dc.journal.number
S1
dc.journal.pagination
S133-S141
dc.journal.pais
Estados Unidos
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.description.fil
Fil: Talevi, Alan. Universidad Nacional de La Plata. Facultad de Ciencas Exactas. Laboratorio de Investigación y Desarrollo de Bioactivos; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata; Argentina
dc.journal.title
Epilepsia Open
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1002/epi4.12581
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1002/epi4.12581
Archivos asociados